LicianPro

Viking Therapeutics, Inc. ·

VKTX 8-K 2026-09-28

Viking Therapeutics, Inc. (VKTX) 8-K dated 2026-09-28 — accession 0001193125-26-405580.

Viking Therapeutics, Inc. (VKTX) is a biotechnology company listed on US.

Viking Therapeutics, Inc. filed a 8-K on 2026-09-28. Accession 0001193125-26-405580.

This 8-K covers: Material agreement (Item 1.01), New debt obligation (Item 2.03), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported VKTX revenue for 2025-12-31 was $0. Net income was -$359.6M. VKTX currently screens at market cap $3.97B.

Not investment advice. The VKTX SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr